REG - Fusion Antibodies - Block admission six monthly return

Fusion AntibodiesAnnouncement

03/10/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20221003:nRSC4115Ba&default-theme=true

RNS Number : 4115B  Fusion Antibodies PLC  03 October 2022

 

Fusion Antibodies plc

("Fusion" or the "Company")

 

Block admission six monthly return

 

Fusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody
discovery, engineering and supply for both therapeutic drug and diagnostic
applications, announces the following information in connection with its
block admission pursuant to AIM Rule 29 and Schedule Six of the AIM Rules for
Companies.

 

 

 Name of company:                                                                Fusion Antibodies plc

 Name of scheme:                                                                 Historic options, EMI and Unapproved Employee Share Option Scheme, as

                                                                               announced on 27 September 2021

 Period of return:                                                               From 2 April 2022 to 1 October 2022

 Number and class of securities not issued under the scheme at the beginning of  787,083 ordinary shares of 4 pence each in the Company ("Ordinary Shares")
 the period:

 Number of securities issued under the scheme during the period:                 Nil

 Number of options under the scheme that have lapsed during the period:          Options over 30,000 Ordinary Shares
 Balance under the scheme of securities not yet issued at the end of the         757,083 Ordinary Shares
 period:

 Number and class of securities originally admitted and the date of admission:   917,083 Ordinary Shares on 27 September 2021

 Contact name and telephone number:                                              James Fair, CFO via Walbrook PR

                                                                                 +44 (0)20 7933 8780

 

 

 

Enquiries:

 

 Fusion Antibodies plc                                 www.fusionantibodies.com
 Adrian Kinkaid, Chief Executive Officer               Via Walbrook PR

 James Fair, Chief Financial Officer

 Allenby Capital Limited                               Tel: +44 (0)20 3328 5656
 James Reeve/Vivek Bhardwaj (Corporate Finance)

 Tony Quirke (Sales and Corporate Broking)

 Walbrook PR               Tel: +44 (0)20 7933 8780 or fusion@walbrookpr.com
 Anna Dunphy                                           Mob: +44 (0)7876 741 001
 Paul McManus                                          Mob: +44 (0)7980 541 893

 

About Fusion Antibodies plc

 

Fusion is a Belfast based contract research organisation ("CRO") providing a
range of antibody engineering services for the development of antibodies for
both therapeutic drug and diagnostic applications.

 

The Company's ordinary shares were admitted to trading on AIM on 18 December
2017. Fusion provides a broad range of services in antibody generation,
development, production, characterisation and optimisation. These services
include antigen expression, antibody production, purification and sequencing,
antibody humanisation using Fusion's proprietary CDRx (TM) platform and the
production of antibody generating stable cell lines to provide material for
use in clinical trials. Since 2012, the Company has successfully sequenced
and expressed over 250 antibodies and successfully completed over 200
humanisation projects and has an international, blue-chip client base, which
has included eight of the top 10 global pharmaceutical companies by revenue.

 

The Company was established in 2001 as a spin out from Queen's University
Belfast. The Company's mission is to enable pharmaceutical and diagnostic
companies to develop innovative products in a timely and cost-effective manner
for the benefit of the global healthcare industry. Fusion Antibodies provides
a broad range of services in antibody generation, development, production,
characterisation and optimisation.

 

Fusion Antibodies growth strategy is based on combining the latest
technological advances with cutting edge science to deliver new platforms that
will enable Pharma and Biotech companies get to the clinic faster, with the
optimal drug candidate and ultimately speed up the drug development process.

 

The global monoclonal antibody therapeutics market was valued at $135.4
billion in 2018 and is forecast to surpass $212.6 billion in 2022, an increase
at a CAGR of 12.0 per cent. for the period 2018 to 2022. In 2017, seven of the
world's ten top selling drugs were antibody-based therapeutics with the
combined annual sales of these drugs exceeding $63.2 billion.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BLRURSSRUUUKOAR